No Data
No Data
No Data
No Data
No Data
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ:MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a t
BenzingaApr 25, 2023 04:00
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC:NMLSF) has started recruiting participants for the first-ever clinical trial assessing
BenzingaApr 20, 2023 21:05
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC:KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a g
Benzinga Real-time NewsFeb 15, 2023 02:42
Nova Mentis Life Science Appoints Executive Chairman
Seeking AlphaJan 18, 2023 21:56
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a
Benzinga Real-time NewsDec 28, 2022 01:51
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB:NMLSF) and Wellbeing Digital Sciences Inc. (OTC:KONEF)'s subsidiary KGK Sciences Inc. have submitted the first-ever Phase 2a Clinical Trial
Benzinga Real-time NewsDec 1, 2022 02:01
No Data
No Data